Healthcare Value Capital 13F annual report

Healthcare Value Capital is an investment fund managing more than $46.2 million ran by Thomas Deschamps. There are currently 18 companies in Mr. Deschamps’s portfolio. The largest investments include Gilead Sciences and Glaxosmithkline plc, together worth $9.15 million.

$46.2 million Assets Under Management (AUM)

As of 9th August 2021, Healthcare Value Capital’s top holding is 75,000 shares of Gilead Sciences currently worth over $5.17 million and making up 11.2% of the portfolio value. Relative to the number of outstanding shares of Gilead Sciences, Healthcare Value Capital owns more than approximately 0.1% of the company. In addition, the fund holds 100,000 shares of Glaxosmithkline plc worth $3.98 million, whose value grew 17.7% in the past six months. The third-largest holding is Pfizer worth $3.92 million and the next is Alkermes plc worth $3.68 million, with 150,000 shares owned.

Currently, Healthcare Value Capital's portfolio is worth at least $46.2 million. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Healthcare Value Capital

The Healthcare Value Capital office and employees reside in Woodcliff Lake, New Jersey. According to the last 13-F report filed with the SEC, Thomas Deschamps serves as the Managing Director, Portfolio Manager at Healthcare Value Capital.

Recent trades

In the most recent 13F filing, Healthcare Value Capital revealed that it had opened a new position in MiMedx Inc and bought 125,000 shares worth $1.56 million. This means they effectively own approximately 0.1% of the company. MiMedx Inc makes up 3.5% of the fund's Health Care sector allocation and has decreased its share price by approximately 0.1% in the past year.

The investment fund also strengthened its position in Alkermes plc by buying 50,000 additional shares. This makes their stake in Alkermes plc total 150,000 shares worth $3.68 million. Alkermes plc dropped approximately 0.1% in the past year.

On the other hand, there are companies that Healthcare Value Capital is getting rid of from its portfolio. Healthcare Value Capital closed its position in Aurinia Pharmaceuticals Inc on 16th August 2021. It sold the previously owned 100,000 shares for $1.3 million.

One of the smallest hedge funds

The two most similar investment funds to Healthcare Value Capital are Covalent Partners and Encap Energy Capital Fund Viii Co-investors, L.P.. They manage $46.2 million and $46.4 million respectively.


Thomas Deschamps investment strategy

Healthcare Value Capital’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 96.6% of the total portfolio value. The fund focuses on investments in the United States as 66.7% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up 33% of the total holdings value. On the other hand, small-cap stocks make up 11.1% of the portfolio. The average market cap of the portfolio companies is close to $53.7 billion.

The complete list of Healthcare Value Capital trades based on 13F SEC filings

These positions were updated on August 16th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security Shares Owned Value Allocation
Gilead Sciences, Inc.
No change
75,000
$5,165,000 11.17%
Glaxosmithkline plc
No change
100,000
$3,982,000 8.61%
Pfizer Inc.
No change
100,000
$3,916,000 8.47%
Alkermes plc
50.00%
150,000
$3,678,000 7.95%
Bristol-Myers Squibb Co.
100.00%
50,000
$3,341,000 7.23%
Merck & Co Inc
100.00%
40,000
$3,111,000 6.73%
Astrazeneca plc
100.00%
50,000
$2,995,000 6.48%
Clovis Oncology Inc
11.11%
500,000
$2,900,000 6.27%
Ironwood Pharmaceuticals Inc
No change
200,000
$2,574,000 5.57%
Amryt Pharma plc
28.57%
200,000
$2,426,000 5.25%
Collegium Pharmaceutical Inc
No change
100,000
$2,364,000 5.11%
Antares Pharma Inc
No change
500,000
$2,180,000 4.71%
Tyme Technologies Inc
No change
1,500,000
$1,890,000 4.09%
VYNE Therapeutics Inc.
12.50%
450,000
$1,580,000 3.42%
Greenlane Holdings Inc
40.00%
350,000
$1,565,000 3.38%
MiMedx Group, Inc
Opened
125,000
$1,564,000 3.38%
Aurinia Pharmaceuticals Inc
Closed
100,000
$1,299,000
Adamas Pharmaceuticals Inc
No change
100,000
$528,000 1.14%
Gamida Cell Ltd
50.00%
75,000
$481,000 1.04%
No transactions found
Showing first 500 out of 19 holdings